Duzallo (DSC)

Drug Overview

Managing severe, chronic gout requires a comprehensive strategy to lower uric acid, halt joint destruction, and restore daily physical function. In the [Rheumatology] category, Duzallo represented a unique, dual-action approach to treating treatment-resistant gout. Classified as a combination Uricosuric and Xanthine Oxidase (XO) Inhibitor, this medication was designed for patients who could not reach their target uric acid levels with standard monotherapy.

It is important to note that Duzallo carries a “DSC” (Discontinued) status. While it was discontinued in certain markets (like the US) primarily for commercial and business reasons, the pharmacological science behind combining these two powerful agents remains highly relevant in modern rheumatological research and specialized patient care globally.

• Generic Name: Lesinurad and Allopurinol
• US Brand Names: Duzallo (DSC)
• Drug Class: Uricosuric / Xanthine Oxidase (XO) Inhibitor
• Route of Administration: Oral (Tablet)
• FDA Approval Status: Originally FDA-approved as a once-daily Small Molecule combination therapy for the treatment of hyperuricemia associated with gout. Currently discontinued (DSC) in the US market, though its active ingredients are still studied and utilized independently or in combination globally.
  
  Read our expert overview of Duzallo (DSC), an essential Uricosuric / XO Inhibitor for treating lesinurad and allopurinol combination. Access trusted medical information and patient resources on our hospital website.

What Is It and How Does It Work? (Mechanism of Action)

Gout is a severely painful form of inflammatory arthritis caused by hyperuricemia—an excess of uric acid in the blood. When uric acid levels remain high, the body forms sharp, microscopic urate crystals that deposit inside the joints, triggering massive immune responses, swelling, and long-term bone erosion.

Duzallo functions as a powerful, dual-action Small Molecule therapy that attacks hyperuricemia from two completely different physiological angles to prevent synovial pannus formation and joint destruction.

First, the allopurinol component acts as a Xanthine Oxidase (XO) inhibitor. Xanthine oxidase is the biological enzyme responsible for converting purines (found in certain foods and dying cells) into uric acid. By inhibiting this enzyme, allopurinol acts upstream, significantly decreasing the body’s overall production of uric acid.

Second, the lesinurad component acts as a Uricosuric agent. It works downstream in the kidneys. Normally, the kidneys filter uric acid out of the blood, but proteins called URAT1 and OAT4 actively reabsorb much of it back into the bloodstream. Lesinurad directly blocks these URAT1 and OAT4 transporter proteins. By preventing reabsorption, it forces the kidneys to excrete higher volumes of uric acid through the urine. Together, this dual “stop production and increase excretion” mechanism aggressively lowers serum uric acid levels, allowing existing crystals to dissolve and preventing new ones from forming.

FDA-Approved Clinical Indications

Because this medication actively manipulates the metabolic pathways of uric acid, its clinical utility is strictly anchored to severe gout management.

• Primary Indication: Indicated for the treatment of hyperuricemia associated with gout in patients who have not achieved target serum uric acid levels with a medically appropriate daily dose of allopurinol alone.
• Other Approved & Off-Label Uses: It is not recommended for the treatment of asymptomatic hyperuricemia. Its active ingredients are sometimes explored in other hyperuricemia-inducing conditions, such as tumor lysis syndrome (allopurinol specifically).

Primary Rheumatology Indications:

• Refractory Gout: Used as a Targeted Therapy to aggressively lower serum uric acid below the therapeutic threshold (typically less than 6.0 mg/dL).
• Tophaceous Gout: Utilized to actively shrink and dissolve tophi (large, visible lumps of urate crystals beneath the skin and around the joints), thereby preventing permanent joint deformity, relieving chronic pain, and improving overall physical function.

Dosage and Administration Protocols

As an oral combination therapy, Duzallo was designed for once-daily convenience, but requires strict adherence to hydration and renal protocols to ensure safety.

Dose Adjustments and Guidelines:

Patients must be adequately hydrated (at least 2 liters of liquid per day) to prevent kidney stones. This medication is contraindicated in patients with severe renal impairment (estimated creatinine clearance less than 30 mL/min), end-stage renal disease, or those on dialysis. It must be taken in the morning with food and water.

“Dosage must be individualized by a qualified healthcare professional.”

Clinical Efficacy and Research Results

While the branded combination pill was discontinued, recent retrospective analyses (2020-2026) continue to validate the clinical efficacy of combining a Uricosuric with an XO Inhibitor for refractory gout. The primary benchmark for success in gout trials is achieving a target serum uric acid (sUA) level of less than 6.0 mg/dL.

In pivotal clinical trials (such as the CLEAR 1 and CLEAR 2 studies which evaluated lesinurad added to allopurinol), the dual-action approach proved highly efficacious. Approximately 54 to 58 percent of patients receiving the combination therapy achieved the target sUA goal by month six, compared to only 28 percent of patients taking allopurinol monotherapy.

By drastically reducing serum uric acid, this Small Molecule combination allows the body to gradually dissolve existing joint crystals. Over a 12-to-24 month period, research demonstrates a significant reduction in acute gout flares and the physical shrinkage of tophi. This chemical dissolution is vital for slowing structural damage, as unresolved tophi physically erode bone and destroy cartilage, mirroring the destructive radiographic progression often seen in untreated Rheumatoid Arthritis.

Safety Profile and Side Effects

BLACK BOX WARNING: RISK OF ACUTE RENAL FAILURE

Lesinurad, one of the active ingredients, carries a Black Box Warning for an increased risk of acute renal failure. This risk is most prominent when the drug is taken without an XO inhibitor, or when patients fail to maintain adequate daily hydration. Regular monitoring of kidney function is absolutely mandatory.

Common Side Effects (>10%):

• Headache and generalized fatigue
• Gastroesophageal reflux disease (GERD) and nausea
• Increased blood creatinine levels (indicating mild kidney stress)

Serious Adverse Events:

• Acute Renal Failure: Sudden loss of kidney function requiring immediate medical intervention.
• Severe Hypersensitivity Reactions: Allopurinol can trigger Stevens-Johnson Syndrome (SJS) or Toxic Epidermal Necrolysis (TEN), which are life-threatening skin rashes.
• Major Adverse Cardiovascular Events (MACE): Some urate-lowering therapies carry generalized cardiovascular warnings, requiring careful patient screening.

Management Strategies:

To mitigate renal toxicity, doctors enforce strict hydration protocols. To prevent severe skin reactions, genetic testing (HLA-B*5801) is strongly recommended for high-risk populations (such as patients of Han Chinese, Korean, or Thai descent) before initiating any allopurinol-containing therapy.

Research Areas

In the 2020-2026 rheumatological research landscape, investigations into gout heavily focus on cartilage preservation and bone remodeling. Urate crystals do not merely cause pain; they actively stimulate osteoclasts (bone-destroying cells) via the RANKL pathway while simultaneously inhibiting osteoblasts (bone-building cells). Active clinical research emphasizes that aggressively clearing these crystals with dual-action Small Molecule therapies is critical to stopping permanent erosive bone disease.

Furthermore, researchers are deeply focused on Severe Disease & Systemic Involvement. Gout is no longer viewed solely as a joint disease. Chronic hyperuricemia is intricately linked to systemic inflammation, heavily increasing the risk of cardiovascular disease, hypertension, and chronic kidney disease. Modern retrospective trials assess how achieving tight uric acid control with combination therapies might prevent these extra-articular manifestations, reducing the overall mortality rate associated with severe, uncontrolled gout.

Disclaimer: The information regarding the Duzallo combination therapy—specifically the Black Box Warning for acute renal failure associated with lesinurad and the severe skin reaction risks (SJS/TEN) associated with allopurinol—is current as of April 2026. While the branded combination product (Duzallo) is discontinued in the US, the pharmacological principles of combining XO inhibitors with uricosuric agents remain a potent strategy for refractory gout management. Strict adherence to renal monitoring and genetic screening prior to initiating allopurinol-containing therapy is a clinical mandate to ensure patient safety. 

Patient Management and Clinical Protocols

Pre-treatment Assessment

Before initiating a powerful combination urate-lowering therapy, a comprehensive clinical baseline must be established.

• Baseline Diagnostics: Joint X-rays or Ultrasounds should be taken to document existing bone erosions and tophi size. Baseline pain scores and frequency of gout flares must be recorded.
• Organ Function: Renal function (eGFR and serum creatinine) must be meticulously evaluated due to the Black Box Warning. Hepatic monitoring (LFTs) is also required, as allopurinol can occasionally cause liver toxicity.
• Specialized Testing: Genetic screening for the HLA-B*5801 allele is critical in specific demographic populations to prevent life-threatening skin reactions.
• Screening: A thorough cardiovascular risk assessment is recommended, given the systemic comorbidities heavily associated with chronic gout.

Monitoring and Precautions

Continuous monitoring ensures the therapy remains effective and prevents severe organ damage.

• Vigilance: Rheumatologists will monitor for acute gout “flares,” which ironically occur frequently when urate-lowering therapy is first started (as crystals begin to shift and dissolve). Prophylactic medications like colchicine are often prescribed simultaneously.
• Lifestyle: Maintaining aggressive hydration (2 to 3 liters of water daily) is non-negotiable to protect the kidneys. An anti-inflammatory, low-purine diet (avoiding organ meats, shellfish, and high-fructose corn syrup) is essential. Total cessation of alcohol, particularly beer, is critical for therapy efficacy.

“Do’s and Don’ts” list:

• DO drink at least 8 to 10 large glasses of water every single day to flush your kidneys and prevent crystal buildup.
• DO take your medication in the morning with food to reduce stomach upset.
• DON’T stop taking the medication if you experience a gout flare. It means the drug is working to dissolve the crystals in your joints.
• DON’T start this medication without discussing your exact kidney health and genetic risks with your prescribing rheumatologist.

Legal Disclaimer

The medical information provided in this guide is intended for educational and informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. Always seek the advice of your physician, rheumatologist, or other qualified healthcare provider with any questions you may have regarding a medical condition, the use of urate-lowering therapies, or before altering your prescribed treatment protocol. Reliance on any information provided in this document is solely at your own risk.